Newsletter | April 30, 2019

04.30.19 -- The Breakthrough April 2019: CAR T Insights And More

Boosting Immuno-Oncology’s Effectiveness Against Cancer

The current limitations on the use of immunotherapy drugs could be swept away thanks to the development of immune checkpoint inhibitors. They block disruptive proteins that limit the body’s natural immune response and stop T cells from destroying cancer cells. Learn how improvements in the methods used for immuno-oncology drug trials could benefit both researchers and patients.

CAR T Cell Therapy And Other Technologies Emerging In Oncology Research

Some unique CAR T cell therapies have already been approved by the U.S. Food and Drug Administration (FDA) and are the first steps toward further groundbreaking science. This webinar reviews the operational and clinical pathways that are helping to bring these technologies to patients.

5 Endpoints For Rare Oncology Trials
For patients battling rare cancers, especially those lacking standard treatments, there's no time to wait for more concrete measures. In these cases, choosing the appropriate endpoint for a trial is crucial. Read on for a rundown of the five major types of clinical endpoints in rare oncology and the best way to use them.
Lengthy Cancer Drug Study Using Dozens Of Sites Yields Positive Results

Recruiting was time consuming, and it took extra effort to ensure that devices used across more than two dozen study sites were accurately calibrated. But for this three-nation study, no factor was more significant than the drug’s own effectiveness. Read this article to learn more.

End-to-End Oncology Development

With wide-ranging experience touching thousands of patients, we cover the spectrum of hematology- and oncology-related therapeutic indications and handle every aspect and phase of drug development in all of them — from small dose-finding studies to large multinational trials.